The effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women: a protocol for systematic review and meta-analysis.
The effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women: a protocol for systematic review and meta-analysis.
复制标题
DOI：
10.1186/s13643-017-0519-2
复制
发表时间：
2017-07-07
影响因子：
3.7
通讯作者：
Ahmed SB
中科院分区：
文献类型：
--
作者：
Dumanski SM;Ramesh S;James MT;Metcalfe A;Nerenberg K;Seely EW;Robertson HL;Ahmed SB
在全球范围内，患有慢性肾脏疾病或面临慢性肾脏疾病风险的妇女的更年期患病率正在上升。尽管国际绝经指南建议使用绝经后激素治疗，并联合或不联合使用选择性雌激素受体调节剂来控制血管舒缩症状，但这些治疗对肾功能和蛋白尿的影响尚不清楚。此外，患有慢性肾脏疾病的妇女患静脉血栓栓塞症和恶性肿瘤的风险显著增加，这是绝经后激素治疗的不良反应。我们的研究旨在确定这些治疗方法对女性肾功能和蛋白尿的影响，并确定这些治疗方法在慢性肾脏疾病人群中的安全性。我们将对绝经后激素治疗和选择性雌激素受体调节剂对女性肾脏结局的影响和安全性进行系统的综述和荟萃分析。我们计划检索所有语言的已发表研究(MEDLINE、EMBASE、Cochrane中央对照试验注册中心(CENTAL)、相关期刊目录)和未发表研究(正在进行的研究、会议记录)，考察绝经后激素治疗(包括选择性雌激素受体调节剂)对肾功能和蛋白尿的影响，以及这些治疗在慢性肾脏疾病女性中的不良结果风险。两名独立的研究人员将筛选已确定的摘要，并选择研究绝经后激素治疗和选择性雌激素受体调节剂对普通人群肾脏结果的影响或对慢性肾脏疾病人群的不良结果的研究。有关研究人群、干预措施、结果以及研究质量和偏倚风险的数据将独立地从每一项合格研究中提取。随着数据的描述性呈现，结果衡量将以使用随机效应模型的荟萃分析的形式呈现。计划的分组分析将完成，如果注意到显著的异质性，将执行Meta回归。通过检查绝经后激素治疗和选择性雌激素受体调节剂对肾功能和蛋白尿的影响，这项系统性综述和荟萃分析的结果将为一般人群中绝经后妇女的管理提供参考。此外，它还将评估安全性，包括在已经脆弱的慢性肾脏疾病人群中，绝经后激素治疗和选择性雌激素受体调节剂的已知不良结果的风险。PROSPERO CRD42016050651本文的在线版本(doi：10.1186/s13643-0170519-2)包含补充材料，授权用户可以使用。
The prevalence of menopause in women with or at risk of chronic kidney disease is increasing globally. Although international guidelines on menopause recommend the use of postmenopausal hormone therapy with or without selective estrogen receptor modulators for control of vasomotor symptoms, the effects of these treatments on kidney function and albuminuria are unclear. Furthermore, women with chronic kidney disease are at significantly increased risk of venous thromboembolism and malignancy, well-documented adverse effects of postmenopausal hormone therapy. Our study aims to establish the effect of these treatments on kidney function and albuminuria in women, as well as determine the safety of these treatments in the chronic kidney disease population. We will conduct a systematic review and meta-analysis addressing the effect and safety of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in women. We plan to search for published (MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), tables of contents of relevant journals) and unpublished (ongoing studies, conference proceedings) studies in all languages examining the effect of postmenopausal hormone therapy, including selective estrogen receptor modulators, on kidney function and albuminuria, as well as the risk of adverse outcomes of these treatments in women with chronic kidney disease. Two independent investigators will screen identified abstracts and select studies that examine the effect of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney outcomes in the general population or adverse outcomes in the chronic kidney disease population. Data on study population, intervention, outcomes, as well as study quality and risk of bias will be independently extracted from each eligible study. Along with descriptive presentation of data, outcome measures will be presented as meta-analyses using a random effects model. Planned subgroup analyses will be completed, and meta-regression will be performed if significant heterogeneity is noted. By examining the effects of postmenopausal hormone therapy and selective estrogen receptor modulators on kidney function and albuminuria, the results of this systematic review and meta-analysis will inform management of postmenopausal women in the general population. Furthermore, it will evaluate the safety, including the risks of known adverse outcomes of postmenopausal hormone therapy and selective estrogen receptor modulators, in the already vulnerable chronic kidney disease population. PROSPERO CRD42016050651 The online version of this article (doi:10.1186/s13643-017-0519-2) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
39
作者：
Avis, Nancy E.;Crawford, Sybil L.;Greendale, Gail;Bromberger, Joyce T.;Everson-Rose, Susan A.;Gold, Ellen B.;Hess, Rachel;Joffe, Hadine;Kravitz, Howard M.;Tepper, Ping G.;Thurston, Rebecca C.
通讯作者：
Thurston, Rebecca C.
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
2.7
作者：
Mao S;Xu H;Zou L;Xu G;Wu Z;Ding Q;Jiang H
通讯作者：
Jiang H
DOI：
10.1136/bmj.f324
发表时间：
2013-01-29
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Nitsch D;Grams M;Sang Y;Black C;Cirillo M;Djurdjev O;Iseki K;Jassal SK;Kimm H;Kronenberg F;Oien CM;Levey AS;Levin A;Woodward M;Hemmelgarn BR;Chronic Kidney Disease Prognosis Consortium
通讯作者：
Chronic Kidney Disease Prognosis Consortium
影响因子：
2.8
作者：
de Villiers, T. J.;Pines, A.;Sturdee, D. W.
通讯作者：
Sturdee, D. W.